Switzerland-based Dualsystems will provide drug and target profiling from clients’ phenotypic assays. In turn, Dualsystems’ clients will have access to medicinal chemistry and early toxicology services at Italy-based NiKem.
“The combined skills that Dualsystems and NiKem can now offer via a single point of contact make for a highly efficient drug discovery engine”, the service providers said in a joint statement.
NiKem was founded in 2001 as a spin-off from GlaxoSmithKline. Dualsystems was founded in the same year as a spin-out from the University of Zurich.